Trials of a potentially curative remedy for type 1 diabetes (T1D) will continue, after the US Food and Drug Administration lifted a clinical hold on the candidate.
Vertex Pharmaceuticals’ (Nasdaq: VRTX) stem cell-derived therapy VX-880 is being tested in a Phase I/II clinical trial, for people with T1D with impaired hypoglycemic awareness and severe hypoglycemia.
Stopping work in May, the FDA said there was “insufficient information to support dose escalation with the product.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze